BioPharma Resources

Investigational drug · Phase 3

Batoclimab

Also called: IMVT-1401

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Eye Disease, Graves Disease.

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

0 still active

All registered trials

7

Any phase or sponsor naming "Batoclimab"

First trial start

2022

Nov 23, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Batoclimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Thyroid Eye Disease
  • Graves Disease

Approved drugs for the same conditions: Endocrinology and women's health

Largest trials

Live from ClinicalTrials.gov: studies naming "Batoclimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 29 on PubMed

Also in development for Thyroid Eye Disease

  • VRDN-003ZL-1109Phase 35 trials

    Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)

  • IBI311Phase 33 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED

  • PacibekitugTOUR006, PAC001Phase 33 trials

    Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases

  • KHN939Phase 32 trials

    Beijing Kanghong Biological Medicine Co., Ltd. · Thyroid Eye Disease

  • linsitinibPhase 32 trials

    Sling Therapeutics, Inc. · Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease

  • AMG 732Phase 22 trials

    Amgen · Thyroid Eye Disease

  • LASN01Phase 22 trials

    Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy

  • lonigutamabPhase 21 trial

    ACELYRIN Inc. · Thyroid Eye Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.